Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PACESS
NCT07102641Phase 4
Key facts
- Status
- Active, not recruiting
- Start
- Aug 2025
- Primary completion
- Jul 2026
- Countries
- 1
- Sponsor
- Thomas Jefferson University
- Modality
- Small Molecules
- Conditions
- Postpartum pain (PPP)
01
Overview
Phase 4, randomised trial of acetaminophen, ketorolac and ibuprofen in Postpartum pain (PPP) (2 arms), sponsored by Thomas Jefferson University. Primary endpoints: Postpartum pain control at 48 hours and Opioid consumption. Started Aug 2025; status: active, not recruiting.
02
Design
2 arms- Study design
- Randomized
Staggered
Medications administered 3H apart (Staggered)
Simultaneous
Medications administered at the same time. (Simultaneous)
03
Who it enrols
Pregnant women >= 34 weeks gestation with a singleton pregnancy undergoing cesarean section under regional anesthesia, excluding those with contraindications to acetaminophen/NSAIDs, history of opioid use, or receiving general anesthesia/local analgesia.
04
Endpoints
Primary
Postpartum pain control
Opioid consumption
Secondary
Postpartum pain
Adequate pain control
Length of stay
Infant feeding
Patient satisfaction
Opioid Prescription
Home opioid
Beyond the preview
Go deeper on NCT07102641.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07102641.